This is the authors' abstract. We don't add key points for this paper.
Notocordal-like cells (NLCs) produced from hiPSCs is considered as a promising candidate for cell-based regenerative therapies to treat intervertebral disk degeneration (IVDD). However, OCT4, SOX2, KLF4, C-MYC (OSKM) reprogramming into iPSC was described to maintain (epi)genomic hallmarks of the origin tissue impacting differentiation abilities. In this context, we produced a three donors-derived unique collection of hiPSCs reprogrammed with OSKM, from two cell types, PBMC and Tie2+ nucleus pulposus-progenitor cells (NPPCs). This collection will allow to further evaluate whether the production of NLCs from iPSCs derived from NPPCs or from PBMC would be the most relevant strategy for hiPSC-based IVDD therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Desprat et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: